News
Penumbra Inc (PEN) reports a 13.4% revenue increase, driven by US thrombectomy success, while navigating international ...
StockStory.org on MSN9h
Penumbra (PEN) Shares Skyrocket, What You Need To KnowWhat Happened? Shares of medical device company Penumbra (NYSE:PEN) jumped 11.8% in the afternoon session after the company ...
Key Points Penumbra topped analyst forecasts with $339.5 million in GAAP revenue and $0.86 non-GAAP EPS, driven by double-digit U.S. thrombectomy growth. Gross margin (GAAP) expanded sharply to 66.0%, ...
In the preceding three months, 7 analysts have released ratings for Penumbra PEN, presenting a wide array of perspectives ...
StockStory.org on MSN1d
Penumbra’s (NYSE:PEN) Q2: Strong Sales, Stock SoarsMedical device company Penumbra (NYSE:PEN) announced in Q2 CY2025, with sales up 13.4% year on year to $339.5 million. The ...
Medical device company Penumbra (NYSE:PEN) will be reporting earnings this Tuesday after market hours. Here’s what you need ...
1don MSN
Explore Penumbra's Q2 2025 earnings highlights, featuring 13.4% growth, U.S. thrombectomy success, RUBY XL launch insights, and updated revenue guidance.
Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second ...
Penumbra’s U.S. thrombectomy business was the standout performer, with revenue jumping 22.6% YoY to $188.5 million. The company’s U.S. venous thromboembolism (VTE) revenue showed particularly strong ...
Penumbra's aspiration-based mechanical thrombectomy devices are building one of the most defensible competitive moats in ...
ALAMEDA, Calif. (AP) — ALAMEDA, Calif. (AP) — Penumbra Inc. (PEN) on Tuesday reported second-quarter earnings of $45.3 million. The Alameda, California-based company said it had net income of $1.15 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results